193 related articles for article (PubMed ID: 25732793)
1. Inhibition of the histone lysine methyltransferase EZH2 for the treatment of cancer.
Verma SK
Curr Top Med Chem; 2015; 15(8):714-9. PubMed ID: 25732793
[TBL] [Abstract][Full Text] [Related]
2. Targeting histone methyltransferase EZH2 as cancer treatment.
Kondo Y
J Biochem; 2014 Nov; 156(5):249-57. PubMed ID: 25179367
[TBL] [Abstract][Full Text] [Related]
3. EZH2 as a potential target in cancer therapy.
McCabe MT; Creasy CL
Epigenomics; 2014 Jun; 6(3):341-51. PubMed ID: 25111487
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic reprogramming in solid tumors: therapeutic implications of EZH2 gain-of-function mutations.
Barsotti AM; Ryskin M; Rollins RA
Epigenomics; 2015 Aug; 7(5):687-90. PubMed ID: 26317265
[No Abstract] [Full Text] [Related]
5. EZH2 in Bladder Cancer, a Promising Therapeutic Target.
Martínez-Fernández M; Rubio C; Segovia C; López-Calderón FF; Dueñas M; Paramio JM
Int J Mol Sci; 2015 Nov; 16(11):27107-32. PubMed ID: 26580594
[TBL] [Abstract][Full Text] [Related]
6. Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors.
Woo J; Kim HY; Byun BJ; Chae CH; Lee JY; Ryu SY; Park WK; Cho H; Choi G
Bioorg Med Chem Lett; 2014 Jun; 24(11):2486-92. PubMed ID: 24767850
[TBL] [Abstract][Full Text] [Related]
7. Targeting EZH2 and PRC2 dependence as novel anticancer therapy.
Xu B; Konze KD; Jin J; Wang GG
Exp Hematol; 2015 Aug; 43(8):698-712. PubMed ID: 26027790
[TBL] [Abstract][Full Text] [Related]
8. Enhancer of zeste homolog-2 (EZH2) methyltransferase regulates transgelin/smooth muscle-22α expression in endothelial cells in response to interleukin-1β and transforming growth factor-β2.
Maleszewska M; Gjaltema RA; Krenning G; Harmsen MC
Cell Signal; 2015 Aug; 27(8):1589-96. PubMed ID: 25917318
[TBL] [Abstract][Full Text] [Related]
9. EZH2 is highly expressed in pituitary adenomas and associated with proliferation.
Schult D; Hölsken A; Siegel S; Buchfelder M; Fahlbusch R; Kreitschmann-Andermahr I; Buslei R
Sci Rep; 2015 Nov; 5():16965. PubMed ID: 26593398
[TBL] [Abstract][Full Text] [Related]
10. Recent progress in the discovery of epigenetic inhibitors for the treatment of cancer.
Verma SK
Methods Mol Biol; 2015; 1238():677-88. PubMed ID: 25421686
[TBL] [Abstract][Full Text] [Related]
11. EZH2 abnormalities in lymphoid malignancies: underlying mechanisms and therapeutic implications.
Li B; Chng WJ
J Hematol Oncol; 2019 Nov; 12(1):118. PubMed ID: 31752930
[TBL] [Abstract][Full Text] [Related]
12. EZH2 Inhibition Blocks Multiple Myeloma Cell Growth through Upregulation of Epithelial Tumor Suppressor Genes.
Hernando H; Gelato KA; Lesche R; Beckmann G; Koehr S; Otto S; Steigemann P; Stresemann C
Mol Cancer Ther; 2016 Feb; 15(2):287-98. PubMed ID: 26590165
[TBL] [Abstract][Full Text] [Related]
13. Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors.
Gibaja V; Shen F; Harari J; Korn J; Ruddy D; Saenz-Vash V; Zhai H; Rejtar T; Paris CG; Yu Z; Lira M; King D; Qi W; Keen N; Hassan AQ; Chan HM
Oncogene; 2016 Feb; 35(5):558-66. PubMed ID: 25893294
[TBL] [Abstract][Full Text] [Related]
14. Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors.
Baker T; Nerle S; Pritchard J; Zhao B; Rivera VM; Garner A; Gonzalvez F
Oncotarget; 2015 Oct; 6(32):32646-55. PubMed ID: 26360609
[TBL] [Abstract][Full Text] [Related]
15. EZH2, an epigenetic driver of prostate cancer.
Yang YA; Yu J
Protein Cell; 2013 May; 4(5):331-41. PubMed ID: 23636686
[TBL] [Abstract][Full Text] [Related]
16. The polycomb group protein enhancer of zeste 2 is a novel therapeutic target for cervical cancer.
Ding M; Zhang H; Li Z; Wang C; Chen J; Shi L; Xu D; Gao Y
Clin Exp Pharmacol Physiol; 2015 May; 42(5):458-64. PubMed ID: 25739318
[TBL] [Abstract][Full Text] [Related]
17. Polycomb Repressive Complex 2 Modulation through the Development of EZH2-EED Interaction Inhibitors and EED Binders.
Tomassi S; Romanelli A; Zwergel C; Valente S; Mai A
J Med Chem; 2021 Aug; 64(16):11774-11797. PubMed ID: 34351144
[TBL] [Abstract][Full Text] [Related]
18. Small molecule inhibitors of EZH2: the emerging translational landscape.
Keilhack H; Smith JJ
Epigenomics; 2015; 7(3):337-41. PubMed ID: 26077423
[No Abstract] [Full Text] [Related]
19. Targeting EZH2 for cancer therapy: progress and perspective.
Han Li C; Chen Y
Curr Protein Pept Sci; 2015; 16(6):559-70. PubMed ID: 25854924
[TBL] [Abstract][Full Text] [Related]
20. EZH2 inhibition enhances the efficacy of an EGFR inhibitor in suppressing colon cancer cells.
Katona BW; Liu Y; Ma A; Jin J; Hua X
Cancer Biol Ther; 2014; 15(12):1677-87. PubMed ID: 25535899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]